Leqvio (Inclisiran) Renal Protection or Renal Risk: What the Evidence Shows

The Bottom Line for Kidney Disease

Inclisiran lowers LDL cholesterol by directing liver cells to break down messenger RNA for PCSK9. The drug is administered by a healthcare professional at the first visit, at 3 months, and every 6 months thereafter. [1]

Kidney disease changes inclisiran exposure, but current evidence has not shown that this requires a different dose. The February 2026 U.S. prescribing information states that no dose adjustment is necessary in mild, moderate, or severe renal impairment. It separately states that Leqvio has not been studied in end-stage renal disease. [1]

Those two statements should not be collapsed into either “unsafe in severe CKD” or “proven safe on dialysis.” Severe renal impairment is included in the no-adjustment language; end-stage renal disease remains an evidence gap.

What the Current FDA Label Actually Says

Approximately 16% of inclisiran is cleared through the kidney. In a dedicated renal-impairment study, peak concentration was about 2.3 to 3.3 times higher and total exposure about 1.6 to 2.3 times higher in people with mild, moderate, or severe renal impairment than in people with normal renal function. Despite those higher plasma exposures, LDL-C reductions were similar across renal-function groups. [1]

The label does not require a special CKD loading schedule, a lower maintenance dose, or a creatinine-based stopping threshold. It also does not prescribe monthly creatinine testing specifically because a patient receives inclisiran. Kidney monitoring should follow the patient's CKD care plan and the clinical context, not an invented Leqvio protocol.

ORION-7: The Dedicated Renal-Impairment Study

ORION-7 (NCT03159416) was the dedicated phase 1 renal study. It included 31 participants with normal kidney function or mild, moderate, or severe renal impairment. A published analysis combined ORION-7 with renal subgroups from ORION-1. [2]

At day 60 in ORION-7, LDL-C fell significantly versus placebo in every renal-function group. The reported reductions were 57.6% in normal renal function, 35.1% in mild impairment, 53.1% in moderate impairment, and 49.2% in severe impairment. Inclisiran exposure rose as renal impairment increased, but drug levels were undetectable in plasma after 48 hours in all groups. The authors concluded that pharmacodynamic effects and safety were similar and that dose adjustment was not required. [2]

ORION-7 was small and was not designed to measure kidney failure, dialysis, eGFR decline, or albuminuria outcomes. It answers a dosing and short-term pharmacology question, not whether inclisiran protects the kidneys.

The 2026 Pooled CKD Analysis

A 2026 post hoc analysis pooled 3,660 participants from ORION-9, ORION-10, and ORION-11. Of these, 300 had baseline eGFR 45 to under 60 mL/min/1.73 m², and 142 had eGFR 15 to under 45. [3]

At day 510, the placebo-corrected LDL-C reductions were 49.9% for eGFR at least 90, 51.2% for eGFR 60 to under 90, 54.7% for eGFR 45 to under 60, and 44.7% for eGFR 15 to under 45. The analysis reported sustained LDL-C lowering and no new safety findings across these groups. [3]

This is stronger CKD-specific evidence than the prior page described, but it remains a post hoc subgroup analysis. It supports consistent cholesterol lowering across eGFR categories; it does not establish a renal-protective effect.

Real-World CKD Data

A 2026 observational study followed 32 patients with CKD and coronary artery disease for 12 months. Mean baseline eGFR was about 37 mL/min/1.73 m². Total and LDL cholesterol fell by nearly 50%, while mean eGFR did not change significantly. [4]

That small uncontrolled study is reassuring but cannot prove safety in every CKD population or show that inclisiran prevents kidney decline. It is best read alongside the randomized trial program, not as a substitute for it.

ORION-18 Was Not a Kidney Trial

ORION-18 is NCT04765657. It enrolled 345 participants in China, South Korea, Singapore, and Taiwan who had ASCVD or high ASCVD risk and elevated LDL-C. Its purpose was to evaluate inclisiran's lipid-lowering efficacy and safety in Asian patients. Published results appeared in 2024. [5, 6]

ORION-18 did not enroll a defined CKD stages 3a-to-4 population, did not have renal protection as its purpose, and is not the prospective renal-outcomes trial previously described on this page. The former NCT04929249 citation was also wrong: that registry record is not ORION-18.

Does Inclisiran Protect the Kidneys?

The answer is not yet established. LDL-C lowering is important for reducing atherosclerotic risk in many patients with CKD, and the 2026 pooled ORION analysis confirms that inclisiran can produce substantial LDL-C reductions across studied eGFR groups. However, cardiovascular risk reduction and direct renal protection are different outcomes. [3]

No cited inclisiran trial has shown that the drug slows long-term eGFR decline, delays dialysis, prevents kidney failure, or produces a sustained reduction in urine albumin-to-creatinine ratio. Preclinical hypotheses about PCSK9 in kidney tissue cannot be presented as clinical benefit.

The evidence-supported wording is therefore:

• Inclisiran produces substantial LDL-C lowering across studied kidney-function groups.
• Current labeling requires no renal dose adjustment through severe renal impairment.
• End-stage renal disease remains unstudied in the label.
• Direct renal protection has not been proven.

A Source-Based CKD Decision Framework

Safety and Drug-Interaction Context

In adult placebo-controlled trials, the current label lists injection-site reactions, arthralgia, and bronchitis as common adverse reactions. The label also includes postmarketing hypersensitivity reactions. [1]

Inclisiran is metabolized by nucleases rather than CYP450 enzymes. The label says it is not expected to cause or be affected by CYP450-mediated interactions, and concomitant inclisiran did not have a clinically significant effect on atorvastatin or rosuvastatin concentrations in population pharmacokinetic analysis. [1]

These pharmacology findings do not remove the need to review the rest of a patient's medication list, kidney status, and indication. They simply correct the unsupported claim that CKD requires a unique inclisiran monitoring protocol.